AU7491396A - Infusions of neuroprotectants and thrombolytic agents - Google Patents

Infusions of neuroprotectants and thrombolytic agents

Info

Publication number
AU7491396A
AU7491396A AU74913/96A AU7491396A AU7491396A AU 7491396 A AU7491396 A AU 7491396A AU 74913/96 A AU74913/96 A AU 74913/96A AU 7491396 A AU7491396 A AU 7491396A AU 7491396 A AU7491396 A AU 7491396A
Authority
AU
Australia
Prior art keywords
neuroprotectants
infusions
thrombolytic agents
thrombolytic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74913/96A
Inventor
Marc Roger De Ryck
Ludwig Norbert Michel Hantson
Luc Remi Mathilde Tritsmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU7491396A publication Critical patent/AU7491396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU74913/96A 1995-10-25 1996-10-21 Infusions of neuroprotectants and thrombolytic agents Abandoned AU7491396A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP95202887 1995-10-25
EP95202887 1995-10-25
EP96201642 1996-06-12
EP96201642 1996-06-12
PCT/EP1996/004609 WO1997015323A1 (en) 1995-10-25 1996-10-21 Infusions of neuroprotectants and thrombolytic agents

Publications (1)

Publication Number Publication Date
AU7491396A true AU7491396A (en) 1997-05-15

Family

ID=26139737

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74913/96A Abandoned AU7491396A (en) 1995-10-25 1996-10-21 Infusions of neuroprotectants and thrombolytic agents

Country Status (4)

Country Link
EP (1) EP0862457A1 (en)
JP (1) JPH11515010A (en)
AU (1) AU7491396A (en)
WO (1) WO1997015323A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510756A (en) * 2003-11-12 2007-04-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Compositions of cyclooxygenase-2 selective inhibitors and neurotrophic factor modulators for treating central nervous system mediated disorders
JP2008230968A (en) * 2005-06-30 2008-10-02 Taisho Pharmaceutical Co Ltd Pharmaceutical for use in the treatment of cerebral infarction
WO2011013668A1 (en) * 2009-07-27 2011-02-03 国立大学法人新潟大学 Pharmaceutical composition for treatment of ischemic events
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds

Also Published As

Publication number Publication date
WO1997015323A1 (en) 1997-05-01
EP0862457A1 (en) 1998-09-09
JPH11515010A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
AU7435296A (en) Novel expression vectors and methods of use
EP0863748A4 (en) Liposomal compositions and methods of using them
AU5644896A (en) Protease variants and compositions
AU7710198A (en) Single pass lead and method of use
AU4896096A (en) Optically active aminoindane derivatives and preparation thereof
AU1372897A (en) 2-amino-heterocycles and therapeutic uses therefor
AU4266596A (en) Composition and use
AU5040896A (en) Benzonitriles and benzofluorides
AU6120994A (en) Anticonvulsive agents and uses thereof
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
AU7621496A (en) Microsensor and use of such microsensor
AU7290898A (en) Preparation of fagopyritols and uses therefor
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU3118297A (en) Sok-1 and methods of use
AU7491396A (en) Infusions of neuroprotectants and thrombolytic agents
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU7139996A (en) Mercaptoamide derivatives and their therapeutic use
AU6975996A (en) Stabilized agchemical concentrate and use thereof
ZA968952B (en) Infusions of neuroprotectants and thrombolytic agents.
AU5188296A (en) Carbopeptoids and carbonucleotoids
AU8750198A (en) Antibiotic preparations and use of the same
AU7298196A (en) Infusions of neuroprotectants and perfluorochemicals
AU5697996A (en) Peptidyl compounds and their therapeutic use
AU7669796A (en) Acylated enol derivatives of alpha-ketoesters and alpha-ketoamides